Survival analysis of palliative radiotherapy in patients with HER-2+ metastatic breast cancer

Survival analysis of palliative radiotherapy in patients with HER-2+ metastatic breast cancer

BackgroundWhether radiotherapy can improve the long-term survival of HER-2+ metastatic breast cancer remains unclear. We launched this study to explore the effect of HER-2+ metastatic breast cancer patients through anti-HER-2 targeted therapy + radiotherapy.Methods488 HER-2 + metastatic breast cance...

Full description

Bibliographic Details
Main Authors:	Xueting Li, Xiaorong Zhong, Hongyu Xu, Jun Wang, Xianguo Liu, Yang Wang, Liang He, Jiayu Ma, Guanghua Li, Lei Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Endocrinology
Subjects:	radiotherapy HER-2 breast cancer overall survival targeted therapy for metastatic breast cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1305429/full

Similar Items

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
by: I-Chun Chen, et al.
Published: (2021-10-01)

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study
by: Yan Chen, et al.
Published: (2024-12-01)

Treatment Outcomes of HER-2 Positive Metastatic Breast Cancer Patients Treated with Pertuzumab in the First Line Setting- Real Life Experience
by: Bekir Hacioglu, et al.
Published: (2019-04-01)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023-02-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
by: Raffaele Ardito, et al.
Published: (2018-09-01)

Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
by: Salvatore Turano, et al.
Published: (2018-09-01)

Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01)

Radiotherapy refusal in breast cancer with breast-conserving surgery
by: Jiameng Liu, et al.
Published: (2023-08-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre
by: Chris Twelves, et al.
Published: (2020-01-01)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan Arlene, et al.
Published: (2012-11-01)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021-08-01)

HER3 receptor and its role in the therapeutic management of metastatic breast cancer
by: Meiying Zhu, et al.
Published: (2024-07-01)

Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block
by: Tea Zeppola
Published: (2018-06-01)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
by: Fabien Moinard-Butot, et al.
Published: (2022-06-01)

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer
by: Yasar Ahmed, et al.
Published: (2022-09-01)

Impact of body mass index on overall survival in patients with metastatic breast cancer
by: Khalil Saleh, et al.
Published: (2021-02-01)

Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort
by: Lizhi Ning, et al.
Published: (2023-10-01)

Good control of diffuse brain metastasis with lapatinib plus capecitabine in a patient with HER2-positive breast cancer
by: Giovanni Faggioni
Published: (2018-06-01)

Additional radiotherapy to breast‐conserving surgery is an optional treatment for de novo stage IV breast cancer: A population‐based analysis
by: Jun Wang, et al.
Published: (2021-03-01)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
by: Yizhao Xie, et al.
Published: (2021-08-01)

The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
by: Jinli Wei, et al.
Published: (2020-06-01)

Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
by: Thibaut Sanglier, et al.
Published: (2022-12-01)

Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study
by: Zhi-wen Li, et al.
Published: (2020-02-01)

Lunga risposta al trattamento di II linea con lapatinib in paziente con secondarismi encefalici da carcinoma mammario HER2-positivo
by: Tiziana Prochilo
Published: (2017-12-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer – a nationwide, retrospective study
by: Alan Celik, et al.
Published: (2024-06-01)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
by: Kümmel S, et al.
Published: (2018-11-01)

Dynamic changes in serum adenosine and the adenosine metabolism-based signature for prognosis in HER2-positive metastatic breast cancer patients
by: Lijun Wang, et al.
Published: (2024-12-01)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
by: Guang-Yi Sun, et al.
Published: (2021-01-01)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
by: Jennifer Y. Ge, et al.
Published: (2021-07-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
by: Juan Jin, et al.
Published: (2023-06-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
by: Natasha B. Hunter, et al.
Published: (2025-02-01)

Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy
by: Hongyu Pu, et al.
Published: (2023-03-01)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
by: Nickolas Stabellini, et al.
Published: (2023-04-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
by: Sophie Frank, et al.
Published: (2020-08-01)

The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery
by: Huanzuo Yang, et al.
Published: (2023-01-01)